Sellas Life Sciences: SLS009 Delivers Real Signals, but the Subgroup Math Demands a Closer Read
Published on 11/05/2026 at 01:40 | Editorial boerse-global.de
The headline number from Sellas Life Sciences' latest update is easy to skim past. The company reported positive results from a completed Phase 2 trial pairing SLS009 with azacitidine and venetoclax in patients whose acute myeloid leukemia had returned after — or never responded to — a venetoclax-based regimen. Across all doses, the combination produced an overall response rate of 34% among 59 evaluable patients, out of 62 enrolled.
That 34% is the broad view. The more eye-catching figures sit beneath it, and the gap between the two is where the investment case actually lives.
Averages Hide the Story
Sellas did not report a uniform effect. Broken out by disease subgroup across all dose levels, the response rate came in at 38% for AML-MR, 44% for monocytic AML, and 36% for TP53-mutated AML. These are the averages that any full read of the trial has to absorb before the highlighted numbers make sense.
The distinction between 62 treated patients and 59 evaluable for efficacy matters too — the two figures are not interchangeable, and neither is the all-dose average a proxy for what happened at the selected dose.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
At 30 mg twice weekly, the picture sharpens considerably. Monocytic AML patients on that schedule posted a 54% response rate, while the TP53-mutated group reached 57%. Those are the numbers drawing attention ahead of the American Society of Hematology meeting in New Orleans, where Sellas will present the full dataset on December 14.
Survival Is the Real Test
Response rates describe how often a treatment achieves a defined effect. What determines clinical potential is whether that translates into longer survival — and here Sellas supplied paired figures rather than response alone.
At the selected dose, median overall survival reached 5.8 months in monocytic AML and 8.8 months in TP53-mutated disease. Against a historical benchmark of roughly 2.5 months for these risk groups, the comparison is encouraging on its face.
It is also the point where caution is warranted. A historical comparison is not a concurrently treated control arm. The survival data offer a promising reference point, not a direct demonstration of superiority over a comparator studied side by side. That distinction should survive even an optimistic reading.
Tolerability, meanwhile, added support without substituting for a full safety assessment. Non-hematologic side effects were mostly grade 1/2 nausea and diarrhea, with no meaningful added toxicity reported.
What Comes Next, and When
The December 14 ASH presentation is the fixed near-term checkpoint. Beyond it, Sellas is running a separate Phase 2 study in 80 newly diagnosed AML patients, with initial summary results expected in the fourth quarter of 2026. That trial addresses a different treatment setting than the post-venetoclax population just reported, so positive findings from the completed study cannot simply be carried over.
The company also expects early summary results from the Phase 3 REGAL study of GPS soon, though no specific date has been given.
Sellas Life Sciences at a turning point? This analysis reveals what investors need to know now.
ASH will not lack for attention. Incyte and Disc Medicine have both flagged presentations on their hematology programs, making the congress a dense cluster of new and updated data. For Sellas, the value lies in clinical detail rather than the buzz of a conference slot.
The Risk Sits in the Subgroups
The strongest counterargument is one of scope. The standout response rates come from specific subgroups at a specific dose. They are neither the result for the full trial population nor a forecast for other treatment settings. An investor who looks only at the selected-dose figures ignores the broader analysis; one who reduces everything to the 34% headline misses the differentiation that gives the release its substance.
Should the coming data fail to support the positive interpretation, expectations would need to be trimmed accordingly — and tolerability alone could not offset weak efficacy. If response and survival hold up, a more favorable view of SLS009's clinical potential is reasonable.
The near-term calendar offers several clinical tests with varying degrees of scheduling certainty. What Sellas delivered today are concrete signals that merit more than a passing glance at a congress announcement. Whether they grow into a durable basis for valuation is a question the December presentation — and the 2026 readouts behind it — will have to answer.
Ad
Sellas Life Sciences Stock: New Analysis - 5 November
Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
